Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

JMP Securities Maintains Market Outperform on Ocular Therapeutix, Raises Price Target to $24

Author: Benzinga Newsdesk | March 12, 2024 10:10am
JMP Securities analyst Jonathan Wolleben maintains Ocular Therapeutix (NASDAQ:OCUL) with a Market Outperform and raises the price target from $12 to $24.

Posted In: OCUL

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist